Abstract:Helios, a transcription factor encoded by IKZF2 of the Ikaros transcription factor family, has an important role in regulating adaptive immune response, not only in regulatory T cells but also in effector T cells. Insights from patients with IKZF2 mutations and translational research in healthy individuals underscore how loss of Helios disrupts immune balance, contributing to pro‐inflammatory T cell phenotypes, dysregulated germinal centre reaction, and premature immune senescence. As drugs targeting Helios enter clinical trials, this review synthesizes evidence from both human and murine studies to highlight its impact on sustaining lymphocyte self‐control. Transcription factor Helios, encoded by the IKZF2 gene, has an important role in regulatory T cells by stabilizing their suppressive phenotype. While Helios is prominently expressed in regulatory T cells, its expression extends beyond to include effector T cells, follicular regulatory T cells, B cells, and innate‐like lymphocyte populations. Recent characterizations of patients with inborn error of immunity due to damaging IKZF2 variants coupled with translational research on lymphocytes from healthy individuals, have increased our understanding on Helios' multifaceted role in controlling the human adaptive immune system. A less studied role for Helios beyond the stabilizing of regulatory T cells has emerged in directing effector T cell maturation. In the absence of functional Helios, effector T cells acquire more inflammatory phenotype and are prone to senescence. Loss of Helios expression disrupts the regulation of the germinal centre reaction, often resulting in either hypogammaglobulinemia or B cell autoimmunity. This review summarizes findings from studies in both mice and men offering a comprehensive understanding of the impact of the transcription factor Helios on the adaptive immune system.

Helios—Illuminating the way for lymphocyte self‐control